Evidence map›Paper›PMID 35971240›Full record

ArticlePediatrics2022

Test-to-Stay After SARS-CoV-2 Exposure: A Mitigation Strategy for Optionally Masked K-12 Schools.

Melissa M Campbell, Daniel K Benjamin, Tara K Mann, Alex Fist, Ashley Blakemore, Kylee S Diaz, Hwasoon Kim, Laura J Edwards, Zsolt Rak, M Alan Brookhart and 11 more

Abstract read
In one paragraph

Article in Pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Measures implemented in the school setting to contain the COVID-19 pandemic.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Melissa M CampbellDuke Clinical Research Institute.
Daniel K BenjaminDuke Clinical Research Institute.
Tara K MannDuke Clinical Research Institute.
Alex FistDuke Clinical Research Institute.
Ashley BlakemoreDuke Clinical Research Institute.
Kylee S DiazDuke Clinical Research Institute.
Hwasoon KimDuke Clinical Research Institute.
Laura J EdwardsDuke Clinical Research Institute.
Zsolt RakDuke Clinical Research Institute.
M Alan BrookhartDepartment of Population Health Sciences.
Zack MooreNorth Carolina Department of Health and Human Services, Raleigh, North Carolina.
Elizabeth Cuervo TilsonNorth Carolina Department of Health and Human Services, Raleigh, North Carolina.
Ibukun KaluDuke Clinical Research Institute.
Angelique E BoutzoukasDuke Clinical Research Institute.
Ganga S MoorthyDuke Clinical Research Institute.
Diya UthappaDoctor of Medicine Program, Duke University School of Medicine, Durham, North Carolina.
Zeni ScottDepartment of Pediatrics.
David J WeberSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Andi L ShaneChildren's Healthcare of Atlanta, Atlanta, Georgia.
Kristina A BryantUniversity of Louisville and Norton Children's Hospital, Louisville, Kentucky.
Kanecia O ZimmermanDuke Clinical Research Institute.

Funding

COVID-19 Supplement - Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)U24TR001608 · NCATS · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K., HERNANDEZ, ADRIAN · 2016 to 2022
$177.0M
RADx-UP SAY YES COVID Test Study (S4)U24MD016258 · NIMHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL, DAVE, GAURAV J · 2020 to 2023
$116.7M
SARS-CoV-2 Screening and Diagnostic testing for return to K-12 schoolsOT2HD107559 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K., ZIMMERMAN, KANECIA OBIE · 2021 to 2022
$5.0M
Unified Program for Therapeutics in Children (UPTiC)T32HD094671 · NICHD · DUKE UNIVERSITY · PI Ian J Davis, Kanecia Obie Zimmerman · 2019 to 2026
$2.9M
NCATS NIH HHS U24 TR001608NICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS OT2 HD107559NICHD NIH HHS T32 HD094671NIMHD NIH HHS U24 MD016258
6 · The paper itself

Abstract

objectivesWe evaluated the impact of a test-to-stay (TTS) program on within-school transmission and missed school days in optionally masked kindergarten through 12th grade schools during a period of high community severe acute respiratory syndrome coronavirus 2 transmission.

methodsClose contacts of those with confirmed severe acute respiratory syndrome coronavirus 2 infection were eligible for enrollment in the TTS program if exposure to a nonhousehold contact occurred between November 11, 2021 and January 28, 2022. Consented participants avoided school exclusion if they remained asymptomatic and rapid antigen testing at prespecified intervals remained negative. Primary outcomes included within-school tertiary attack rate (test positivity among close contacts of positive TTS participants) and school days saved among TTS participants. We estimated the number of additional school-acquired cases resulting from TTS and eliminating school exclusion.

resultsA total of 1675 participants tested positive or received at least 1 negative test between days 5 and 7 and completed follow-up; 92% were students and 91% were exposed to an unmasked primary case. We identified 201 positive cases. We observed a tertiary attack rate of 10% (95% confidence interval: 6%-19%), and 7272 (89%) of potentially missed days were saved through TTS implementation. We estimated 1 additional school-acquired case for every 21 TTS participants remaining in school buildings during the entire study period.

conclusionsEven in the setting of high community transmission, a TTS strategy resulted in substantial reduction in missed school days in optionally masked schools.

Indexed as

COVID-19SARS-CoV-2HumansIncidenceSchools

Identifiers

PMID35971240
PMCPMC9647593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.